FDA OK's Onivyde In Pancreatic Cancer; Warnings Smack Merrimack
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals Inc. won the FDA's approval on Oct. 22 to market Onivyde (irinotecan liposome injection), an topoisomerase inhibitor, as a treatment in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.